Hemcheck has received a first order from Kuressaare hospital in Estonia. The order is of lower economic value however there is potential for additional follow up orders. This will be Hemcheck’s third customer in Estonia after Tartu University Hospital and Narva Hospital.
– We continue to get more customers in Estonia which is very good news. Even if this first order is of lower economic value, it is important since we have a good trend in the Estonian market and it is a first step towards a potentially larger collaboration with the hospital, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
About Kuressaare hospital
Read more at https://www.saarehaigla.ee/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.